Experimental evidence on antidiabetic medicine reported that a greater than 6-times increase in the risk of acute pancreatitis was found among individuals who use type 2 diabetes medications, such as sitagliptin (a dipeptidyl peptidase 4 inhibitor) and exenatide (a glucagon-like peptide 1 analogue)24. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.